A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

Running, not enrolling · Phase 1

Conditions studied: Age-Related Macular Degeneration

In brief

The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.

Key facts

Study ID

NCT01678872

Run by

Oxford BioMedica

People needed

18

Starts

2012-08-01

Expected to finish

2029-03-01

Last updated by the study team

2026-01-14

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have received a subretinal injection of RetinoStat
• Must have been enrolled in Protocol RS1/001/10

You may not qualify if…

• Did not receive RetinoStat® as part of the RS1/001/10 protocol

Where it is running

• University of Iowa Hospitals & Clinics — Iowa City, Iowa, United States
• John Hopkins University Hospital — Baltimore, Maryland, United States
• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.